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Background:  Diabetes mellitus is a major independent risk factor for cardiovascular disease (CVD), but high cardiovascular risk 
in diabetes mellitus patients is not completely explained by clustering traditional risk factors. Recently, associations between dia-
betic polyneuropathy (DPN) and macrovasculopathy have been suggested. We aimed to assess associations between DPN and 
cardiovascular complications in type 2 diabetic patients. 
Methods:  Microvascular and cardiovascular complications were evaluated in 1,041 type 2 diabetic patients. 
Results:  In patients with DPN, the age, prevalence of hypertension, diabetes duration, systolic blood pressure, pulse pressure, and 
hemoglobin glycation (HbA1c) levels were significantly higher, while the high density lipoprotein cholesterol (HDL-C) levels 
were lower than in those without DPN. The prevalence of CVD was higher in patients with DPN. In multivariate analysis, DPN 
was independently associated with CVD (odds ratio, 1.801; 95% confidence interval, 1.009 to 3.214). 
Conclusion:  Our results showed that DPN was associated with a high prevalence of cardiovascular disease in type 2 diabetic 
patients, but further studies are needed to investigate the causative nature of associations between DPN and CVD.
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INTRODUCTION
Type 2 diabetes mellitus is the major cause of blindness, end-
stage renal disease, and non-traumatic amputation. Diabetes 
mellitus is also a major independent risk factor for cardiovas-
cular disease such as ischemic heart disease and stroke [1]. This 
high cardiovascular risk is not completely explained by clus-
tering traditional risk factors. In this regard, additional linkage 
between diabetes mellitus and increased cardiovascular mor-
bidity and mortality might be related to the development of 
microvascular complications, such as albuminuria, decreased 
glomerular filtration rate, retinopathy, and cardiovascular au-
tonomic neuropathy [2-4].
  Diabetic polyneuropathy (DPN) is one of the microvascular 
complications of diabetes that is attributed to chronic hyper-
glycemia and is a common cause of morbidity in patients with 
diabetes mellitus [5]. The major morbidity associated with 
DPN is foot ulceration, predisposition to gangrene, and limb 
loss [5]. Calcification of the media of arterial walls is common 
in patients with diabetes mellitus. Recently, some studies have 
reported that DPN is associated with medial arterial calcifica-
tion in diabetes mellitus [6,7]. Young et al. [7] reported that 
medial arterial calcification correlated with vibration percep-
tion threshold. Medial arterial calcification is known to be as-
sociated with coronary heart disease and all-cause mortality 
[8,9]. Thus, DPN might be directly related to cardiovascular 
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disease. However, relationships between DPN and cardiovas-
cular disease in type 2 diabetic patients are not fully under-
stood. In the present study, we aimed to assess associations be-
tween DPN and cardiovascular complications in type 2 dia-
betic patients.
METHODS
This study was an observational study designed to investigate 
the prevalence of chronic complications in type 2 diabetic pa-
tients. The data was obtained from September 2008 to August 
2009. The study was approved by the Ethics Committee of 
Chonnam National University Hospital. All participants gave 
informed consent. A total of 1,041 patients with type 2 diabe-
tes mellitus diagnosed after the age of 35 years who visited our 
hospital to evaluate chronic diabetic complications were inves-
tigated. Patients having any of the following characteristics were 
excluded from the study: active liver disease, glucocorticoid 
use, positive GAD autoantibodies, malignancy or primary 
neurologic disorders (previous spinal injury, a history of lum-
bar or cervical discopathies, carpal tunnel syndrome, alcoholic 
neuropathy, inherited neuropathy). A history and physical ex-
amination, including measurements of blood pressure, height, 
and body weight, were performed. Body mass index was cal-
culated as weight (kg) divided by the square of height (m
2). 
Blood pressure was measured twice in a sitting position at a 
5-minute interval after 30 minutes of rest, and the mean values 
were calculated. Pulse pressure was calculated as the difference 
between systolic and diastolic blood pressures. Hypertension 
was considered if the patient had a blood pressure greater than 
140/90 mm Hg or used antihypertensive drugs. Smoking was 
defined as never/past or current. 
  Blood samples were collected after a 10 to 12 hour overnight 
fast. The plasma glucose level was measured using the hexoki-
nase method (Hitach 7600-110; Hitachi Co., Tokyo, Japan), and 
HbA1c was measured using ion exchange liquid chromatogra-
phy (HLC-723-GHbV; Tosoh, Tokyo, Japan). Levels of total 
cholesterol (AU 5400; Olympus, Tokyo, Japan), high density 
lipoprotein cholesterol (HDL-C) (AU5400), low density lipo-
protein cholesterol (LDL-C) (AU5400), and triglycerides 
(AU5400) were measured. High-sensitivity C-reactive protein 
was measured using the BNTM system (N High Sensitivity 
CRP; Dade Behring, Marburg, Germany). 
  Urinary albumin excretion was determined using the uri-
nary albumin: creatinine ratio (UAE) in random urine sam-
ples. The urinary albumin concentration was measured using 
the immunoturbidimetric method with a commercial kit 
(Randox, Antrim, UK). Nephropathy was defined as UAE 
≥300 mg/gCr in two of three urine collections. To evaluate 
retinopathy, an ophthalmologist performed fundoscopy after 
pupillary dilation. In addition to a clinical neurological exami-
nation, peripheral neuropathy was assessed through the mea-
surement of peripheral nerves with an electroneuromyograph-
ic device (Medelec Synergy; Oxford Instruments, Oxford, UK). 
Motor and sensory amplitudes, conduction velocities, F re-
sponses and latencies were recorded. If two or more different 
nerves showed abnormal findings greater than two standard 
deviations from the normal range in three or more of four pa-
rameters, the patient was determined as having neurophysio-
logically diagnosed peripheral polyneuropathy [10,11]. Deep 
breathing (E/I ratio), Valsalva and posture tests were used to 
assess cardiovascular autonomic function with the Monitor 
one nDx (QMed Inc., Entontown, NJ, USA). Cardiovascular 
autonomic neuropathy was diagnosed in patients having at 
least two abnormal tests: an abnormal E/I ratio based on age-
adjusted norms, a Valsalva ratio <1.2 or a 30:15 ratio <1.03.
  Coronary heart disease and cerebrovascular disease were 
defined as cardiovascular disease. A diagnosis of coronary 
heart disease was based on a history of myocardial infarction, 
angina pectoris or ischemic heart disease, coronary artery an-
gioplasty, or pathological findings coded using Minnesota codes 
1.1 to 3, 4.1 to 4, and 5.1 to 3 in the resting electrocardiogram 
[12]. Cerebrovascular disease (CVD) was defined according to 
medical records, if pathological findings such as ischemic stroke 
on computed tomography or an area of low signal intensity 
measuring at least 3 mm on T1-weighted images and a hyper-
intense lesion on T2-weighted images on magnetic resonance 
imaging of the brain had been documented [13]. 
Statistical analysis
Data were expressed as the mean±standard deviation, unless 
otherwise stated. A χ
2 test was used to determine significance, 
if any, in the differences measured between groups for each vari-
able. Continuous variables were analyzed using Mann-Whitney 
U test or a Student’s t-test. Multivariate logistic regression analy-
ses were performed to determine associations between DPN 
and other diabetic complications. Using the logistic regression 
model with the forward Wald method, multivariate analyses 
were performed with identified independent variables and 
factors previously reported to have independent associations 392
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in order to analyze the association of DPN with cardiovascular 
disease. Statistical analysis was performed using SPSS software 
version 17.0 (SPSS Inc., Chicago, IL, USA). A P value of less 
than 0.05 was considered statistically significant.
RESULTS
The mean age of the participants was 62.6±11.1 years; diabetes 
duration and HbA1c level were 12.2±7.7 years and 8.1±2.0%, 
respectively. The treatment methods for diabetes were: lifestyle 
modification alone (6.8%), oral hypoglycemic agents alone 
(61.2%), insulin dosing (11.8%), or a combination of oral hy-
poglycemic agents and insulin (20.2%). The clinical findings 
and laboratory data of type 2 diabetic patients, with and with-
out DPN, are shown in Table 1. Of a total of 1,041 type 2 dia-
betic patients, 550 patients were in the DPN group. In patients 
with DPN, the age, prevalence of hypertension, diabetes dura-
tion, systolic blood pressure, pulse pressure, and HbA1c level 
were significantly higher, while the HDL-C level was signifi-
cantly lower compared to those in patients without DPN. Af-
ter age adjustment, there were also significant differences in 
systolic blood pressure, diabetes duration, pulse pressure and 
HbA1c between patients with and without DPN (P<0.05, re-
spectively). In motor and sensory nerve studies, there were 
significant differences between patients with and without DPN 
(Table 1). The prevalence of diabetic retinopathy, nephropathy, 
or autonomic neuropathy was higher in patients with DPN, 
remaining significant after adjustment for age, diabetes dura-
tion, and hypertension (Table 2).
  CVD was significantly associated with increased age, greater 
prevalence of hypertension, longer diabetes duration, a wider 
range in pulse pressure, and higher HbA1c level (Table 3). The 
prevalence of diabetic retinopathy, nephropathy or DPN was 
higher in patients with CVD. To identify the significant inde-
pendent determinants for CVD in all patients, logistic regres-
sion analyses were performed. In univariate analysis, DPN was 
associated with CVD (odds ratio [OR], 2.043; 95% confidence 
interval [CI], 1.434 to 2.910). For the multivariate analysis, we 
included the identified independent variables and factors pre-
viously reported to have independent associations with CVD. 
Here, DPN was independently associated with CVD (OR, 
1.947; 95% CI, 1.169 to 3.241) (Table 4). When retinopathy, 
nephropathy, and autonomic neuropathy were also included 
in this model (model 2), DPN was also independently associ-
ated with CVD (OR, 1.801; 95% CI, 1.009 to 3.214).
DISCUSSION
In this study, our results showed that other diabetic complica-
tions, e.g., diabetic retinopathy and nephropathy were more 
prevalent in type 2 diabetic patients with DPN. Also, we found 
that there was a strong association between DPN and CVD 
prevalence in type 2 diabetic patients. 
  Type 2 diabetic patients with DPN had longer diabetes du-
ration and higher HbA1c levels than those without DPN sup-
porting previous studies [14,15]. Also, DPN was associated 
with higher prevalence of retinopathy and nephropathy. Sev-
eral prior studies have suggested that DPN is closely associated 
with diabetic retinopathy. O′Hare et al. [16] showed that dia-
betic neuropathy was associated with retinopathy in type 2 di-
abetes mellitus. Cohen et al. [17] demonstrated that DPN was 
associated with the high prevalence of both retinopathy and 
overt proteinuria in type 2 diabetic patients. However, a rela-
tionship between DPN and diabetic nephropathy has not been 
consistently demonstrated. Shaw et al. [18] reported that a sig-
nificant proportion of type 1 diabetic patients with diabetic 
nephropathy did not have diabetic peripheral neuropathy. Re-
cently, Karvestedt et al. [19] reported that DPN was more 
common in type 2 diabetic patients with overt proteinuria than 
it was in those without overt proteinuria. Results from these 
prior studies, in conjunction with our findings, suggest a close 
relationship between neuropathy and nephropathy, as well as 
between neuropathy and retinopathy. 
  DPN is known to predict foot ulceration, lower-extremity 
amputation, and mortality [20]. The presence of cardiovascu-
lar autonomic neuropathy contributes to a higher mortality 
rate in patients with diabetes mellitus, in part due to asymp-
tomatic (painless) myocardial ischemia and hence delayed di-
agnosis [2]. Recently, associations between DPN and macro-
vasculopathy have been suggested [21,22]. Coppini et al. [23] 
showed that higher vibration perception thresholds were more 
strongly associated with increased mortality than were other 
microvascular complications in diabetic patients. Forsblom et 
al. [24] reported that neurophysiologically diagnosed neurop-
athy might have a direct role for cardiovascular mortality in 
type 2 diabetes. In the Detection of Ischemia in Asymptomatic 
Diabetics (DIAD) study, a significant relation to CVD outcomes 
such as nonfatal myocardial infarction and cardiac death was 
found with symptom (numbness) and sign (absent sensation) 
of peripheral polyneuropathy [25]. The Action to Control Car-
diovascular Risk in Diabetes (ACCORD) trial suggested the 393
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Table 1. Characteristics of type 2 diabetic patients with or without diabetic polyneuropathy
Characteristic DPN (-) (n=491) DPN (+) (n=550) P value
Age, yr 59.3±11.5 65.7±9.5 <0.001
Male, n (%) 227 (46.2) 265 (48.2) 0.529
Smoking, n (%) 131 (26.7) 131 (23.8) 0.288
Hypertension, n (%) 215 (43.8) 355 (64.5) <0.001
Diabetes duration, yr 10.4±6.6 13.8±8.2 <0.001
BMI, kg/m
2 24.8±3.4 24.9±3.3 0.624
SBP, mm Hg 130.0±15.3 133.8±17.5 0.001
DBP, mm Hg 76.6±10.5 76.9±11.2 0.665
Pulse pressure, mm Hg 53.3±11.4 57.0±12.4 <0.001
Fasting glucose, mg/dL 148.7±52.3 155.8±59.6 0.262
HbA1c, % 7.9±2.0 8.2±1.9 0.010
TC, mg/dL 177.8±42.7 179.2±50.5 0.574
TG , mg/dL 121.0 (108.0) 125.0 (93.0) 0.280
HDL-C, mg/dL 51.1±33.9 47.9±13.7 0.046
LDL-C, mg/dL 111.3±49.8 110.0±35.5 0.556
hs-CRP, mg/dL 0.09 (0.20) 0.11 (0.34) 0.139
Motor nerve conduction studies
Median nerve Distal latency, msec 7.7±0.8 8.8±1.3 <0.001
Amplitude, mV 14.6±4.3 11.9±4.0 <0.001
Conduction velocity, m/sec 55.5±5.3 51.4±4.9 <0.001
F-wave, msec 26.1±2.5 28.9±4.0 <0.001
Ulnar nerve Distal latency, msec 6.5±0.9 7.2±1.1 <0.001
Amplitude, mV 14.0±2.8 12.0±3.1 <0.001
Conduction velocity, m/sec 56.9±6.6 52.6±5.7 <0.001
F-wave, msec 26.1±3.6 28.4±4.4 <0.001
Peroneal nerve Distal latency, msec 10.0±1.5 11.1±2.2 <0.001
Amplitude, mV 5.9 (3.8) 4.2 (3.9) <0.001
Conduction velocity, m/sec 46.5±4.2 41.6±6.0 <0.001
F-wave, msec 46.7±4.8 51.7±7.6 <0.001
Tibial nerve Distal latency, msec 11.6±2.0 12.8±2.1 <0.001
Amplitude, mV 17.8 (9.4) 14.1 (7.6) <0.001
Conduction velocity, m/sec 45.6±6.2 40.8±5.5 <0.001
F-wave, msec 46.6±6.4 51.9±8.0 <0.001
Sensory nerve conduction studies
Median nerve Distal latency, msec 3.2 (0.5) 3.6 (0.9) <0.001
Amplitude, mV 24.0 (15.2) 14.8 (11.6) <0.001
Ulnar nerve Distal latency, msec 3.2 (0.4) 3.4 (0.5) <0.001
Amplitude, mV 22.1 (12.5) 15.8 (10.7) <0.001
Superficial peroneal nerve Distal latency, msec 3.6±0.5 4.0±0.5 <0.001
Amplitude, mV 10.6 (2.6) 6.4 (4.0) <0.001
Sural nerve Distal latency, msec 3.5±0.7 3.9±0.5 <0.001
Amplitude, mV 13.9 (6.0) 8.6 (5.6) <0.001
Data are mean±standard deviation or median (interquartile range). Number in parenthesis is percentage. Analyzed using Mann-Whitney U 
test, Student’s t-test or χ
2 test. 
DPN, diabetic polyneuropathy; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HbA1c, hemoglobin glyca-
tion; TC, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; hs-CRP, 
high-sensitivity C-reactive protein.394
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possible role of cardiac autonomic neuropathy and peripheral 
polyneuropathy as a strong predictor for CVD mortality [26]. 
Also, some studies have demonstrated that distal symmetrical 
neuropathy is associated with medial arterial calcification in 
diabetes mellitus patients [6,7], which has been reported to be 
associated with an increase in coronary heart disease and all-
cause mortality in type 2 diabetes mellitus patients [8,9]. Yo-
shida et al. [27] reported that the extent of coronary artery cal-
cification measured by electron beam computed tomography 
was significantly higher in patients with DPN. In the present 
study, DPN was associated with a high prevalence of risk fac-
tors for macrovascular complications, such as poor metabolic 
control, dyslipidemia, hypertension, increased pulse pressure, 
and albuminuria. Also, DPN was associated with a high preva-
lence of CVD in type 2 diabetes patients. Thus, the results in 
the present study may support a common pathogenic mecha-
nism as the relationship between neuropathy and macrovas-
cular complications [19,22,28-30], suggesting the roles of vas-
cular and metabolic factors. However, further studies are need-
ed to investigate the mechanism that links DPN with cardio-
vascular complications. 
  This study has some limitations. Although nerve electro-
physiologic studies are the sensitive, objective and highly re-
producible means of investigating diabetic polyneuropathy 
and have a key role in the elimination of other causes of neu-
ropathy, they have limitations in the assessment of small-fiber 
dysfunction [10]. Also, because our study was cross-sectional, 
the causative natures of the associations between DPN and 
Table 2. Associations of diabetic polyneuropathy (DPN) with 
other microvascular complications in type 2 diabetic patients
Variable Present aOR
a 95% CI P value
Retinopathy
DPN (-) (n=491) 121/491 (24.6) 1.00
DPN (+) (n=550) 270/550 (49.1) 2.219 1.593-3.090 <0.001
Nephropathy
DPN (-) (n=491) 51/491 (10.4)  1.00
DPN (+) (n=550) 100/550 (18.2) 1.808 1.144-2.585 0.011
Autonomic neuropathy
DPN (-) (n=491) 150/491 (30.5) 1.00
DPN (+) (n=550) 202/550 (36.7) 1.779 1.065-2.971 0.028
Number in parenthesis is percentage. Analyzed using χ
2 test and mul-
tivariate logistic regression.
OR, odds ratio; CI, confidence interval.
aAdjusted for age, diabetes duration and hypertension.
Table 4. Multivariate logistic regression analysis with CVD as 
a dependent variable
Variable aOR
a  95% CI P value
Model 1
DPN (-, +) 1.947 1.169-3.241 0.010
Model 2 
DPN (-, +) 1.801 1.009-3.214 0.046
OR, odds ratio; CI, confidence interval.
aModel 1: adjusted for age, sex, smoking, body mass index, hyperten-
sion, HbA1c, diabetes duration, low density lipoprotein cholesterol, 
high density lipoprotein cholesterol, and pulse pressure; Model 2: 
model 1 plus retinopathy, nephropathy, and autonomic neuropathy.
Table 3. Characteristics of type 2 diabetic patients in associa-
tion with cardiovascular complications
Characteristic CVD (-) CVD (+) P value
No. 879 162
Age, yr 62.0±11.2 66.4±8.7 <0.001
Male, n (%) 408 (46.4) 84 (51.9) 0.203
Smoking, n (%) 213 (24.2) 49 (30.2) 0.105
Hypertension, n (%) 454 (51.6) 116 (71.6) <0.001
Diabetes duration, yr 11.5±7.2 15.7±8.9 <0.001
BMI, kg/m
2 24.8±3.4 25.2±3.2 0.257
SBP, mm Hg 131.4± 16.4 135.3±17.4 0.006
DBP, mm Hg 76.5±10.8 78.4±11.0 0.049
Pulse pressure, mm Hg 54.8±11.9 57.3±12.6 0.022
Fasting glucose, mg/dL 150.4±52.3 161.9±70.1 0.163
HbA1c, % 8.0±1.8 8.6±2.7 0.006
TC, mg/dL 179.5±47.7 173.4±42.5 0.128
TG, mg/dL 123.0 (97.0) 132.0 (101.0) 0.280
HDL-C, mg/dL 49.8±26.8 47.2±15.2 0.233
LDL-C, mg/dL 111.3±41.7 106.7±47.8 0.207
hs-CRP, mg/dL 0.10 (0.26) 0.12 (0.52) 0.109
Retinopathy, n (%) 311 (35.4) 80 (49.4) 0.001
Nephropathy, n (%) 114 (13.0) 37 (22.8) 0.001
DPN, n (%) 441 (50.2) 109 (67.3) <0.001
CAN, n (%) 296 (33.7) 56 (34.6) 0.825
Data are mean±standard deviation or median (interquartile range). 
Number in parenthesis is percentage. Analyzed using Mann-Whit-
ney U test, Student’s t-test or χ
2 test. 
CVD, cardiovascular disease; BMI, body mass index; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; HbA1c, hemoglobin 
glycation; TG, triglyceride; HDL-C, high density lipoprotein choles-
terol; LDL-C, low density lipoprotein cholesterol; hs-CRP, high-sen-
sitivity C-reactive protein; DPN, diabetic polyneuropathy; CAN, car-
diovascular autonomic neuropathy.395
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CVD cannot be established. Further investigation is necessary 
to evaluate whether DPN is associated with incident CVD 
among type 2 diabetic adults and to determine possible mech-
anisms between DPN and CVD adverse outcomes. 
  In conclusion, this study shows that DPN is associated with 
a high prevalence of cardiovascular disease in type 2 diabetic 
patients and suggests that type 2 diabetic patients with DPN 
may warrant a more careful cardiovascular assessment and 
follow-up. 
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